Pluvicto vs ARPI in Prostate Cancer: Is One Better?
Patients with metastatic castration-resistant prostate cancer who received Lu-177-PSMA-617 (Pluvicto) achieved similar overall survival and had fewer serious adverse events compared to those who switched androgen receptor pathway inhibitors (ARPI) after progressing on a first-line ARPI. However, the authors noted, the overall survival results "were likely confounded by the high rate of crossover" from a second-line ARPI to Lu-177-PSMA-617.
METHODOLOGY:
Patients with metastatic castration-resistant prostate cancer who progress on first-line ARPI therapy and are taxane-naive may receive an ARPI in the second-line setting if they are unable to tolerate taxane-based chemotherapy. However, an ARPI is not the most active treatment in this setting.
In the PSMAfore trial , researchers compared the efficacy of another agent — Lu-177-PSMA-617 — to an ARPI as a second-line treatment option. Overall, 468 patients with PSMA-positive metastatic castration-resistant prostate cancer were randomly assigned to receive either Lu-177-PSMA-617 (n = 234) or ARPI switch (n = 234). Participants had previously experienced disease progression on an ARPI (abiraterone, enzalutamide, darolutamide, or apalutamide) and were deemed appropriate to delay taxane-based chemotherapy.
Participants received Lu-177-PSMA-617 at a dose of 7.4 GBq once every 6 weeks for six cycles or ARPI change (abiraterone or enzalutamide at the treating physician's discretion). Patients in the ARPI arm could cross over to Lu-177-PSMA-617 after centrally confirmed radiographic progression.
In the initial analysis, radiographic progression-free survival appeared longer in patients receiving Lu-177-PSMA-617 compared to a second-line ARPI. During the final analysis , 60.3% of participants (141 of 234) randomly assigned to the ARPI switch group crossed over to receive Lu-177-PSMA-617, representing 75.4% of patients with confirmed radiographic progression.
The median duration of exposure was 8.41 months in the Lu-177-PSMA-617 arm, 6.54 months in the ARPI-change arm, and 7.16 months in the crossover group.
TAKEAWAY:
Median overall survival was similar in both groups: 24.48 months with Lu-177-PSMA-617 vs 23.13 months with ARPI change (hazard ratio [HR], 0.91; P = .20), according to the intention-to-treat analysis.
In a crossover-adjusted analysis, patients receiving Lu-177-PSMA-617 demonstrated a significant survival benefit (HR, 0.59), which "suggested that treatment crossover likely confounded [overall survival]," the authors wrote.
Treatment-emergent adverse events of grade 3 or higher were lower in the Lu-177-PSMA-617 group, as were rates of serious adverse events of any grade.
In the Lu-177-PSMA-617 arm, more common adverse events included dry mouth and anemia. Dry mouth of any grade occurred in nearly 60% of participants, with less than 1% experiencing events of grade 3 or higher. Anemia of any grade occurred in about 27% of patients, with 6.2% experiencing events of grade 3 or higher. These events were predominantly low grade and resolved or were resolving at the final analysis.
IN PRACTICE:
Taken together with the previous observations from PSMAfore, "these results further support 177Lu-PSMA-617 as an alternative treatment option to ARPI change" in this patient population, the authors wrote.
SOURCE:
The study, led by Karim Fizazi, PhD, Institut Gustave Roussy and Centre Oscar Lambret, Université Paris-Saclay in Villejuif, France, was published online in Annals of Oncology.
LIMITATIONS:
The high rate of crossover probably confounded the overall survival analysis. The study excluded patients with known genomic alterations, limiting generalizability. Additionally, the trial may have been underpowered to detect an overall survival difference between arms, a limitation further exacerbated by the high crossover rate.
DISCLOSURES:
This study was funded by Novartis. Four authors reported being employees of and receiving restricted stock options from Novartis. Several authors reported receiving research grants or honoraria and having other ties with various sources. Additional disclosures are noted in the original article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
3 hours ago
- Associated Press
Society of Interventional Oncology Announces First Site Approved for Enrollment in TRIBUTE Trial
A Multi-Center Observational Trial of Symptomatic, High-Risk Bone Metastases Treated with Percutaneous Ablation and Palliative Radiation Therapy WASHINGTON, D.C. / ACCESS Newswire / August 18, 2025 / The Society of Interventional Oncology (SIO) proudly announces that the Washington University School of Medicine in St. Louis, MO, USA, has been the first site approved and activated for enrollment in the society's second clinical trial, TRIBUTE: A Multi-Center Observational Trial of Symptomatic, High-Risk Bone Metastases Treated with Percutaneous Ablation and Palliative Radiation Therapy. The Washington University School of Medicine site study physicians are Jack Jennings, MD, PhD, FSIR, and Clifford Robinson, Trial Drs. Jennings and Robinson are two of four physicians leading the TRIBUTE Trial, including Sean Tutton, MD, FSIR, FCIRSE, and James Urbanic, MD, from the University of California, San Diego. 'We are excited and pleased to share that Washington University School of Medicine, St. Louis, is our first site activated and is ready for patient enrollment in the TRIBUTE Trial,' said Jennings. 'We look forward to announcing other sites in the U.S. as they are approved for enrollment.' The TRIBUTE study is collectively supported by the study's Exclusive Pioneer Trial Partner, Varian, a Siemens Healthineers Company, the study's Catalyst Trial Partner, Stryker, Inc., and the study's Advocate Trial Partner, Boston Scientific Corporation. This is the first prospective, multi-center study to evaluate real-world outcomes (e.g., pain, patient reported outcomes, skeletal related events, healthcare utilization, etc.) in adult patients treated with both percutaneous ablation and palliative radiation therapy (RT) for symptomatic, high-risk metastatic bone lesions. The study was collaboratively designed and developed with the partnership of radiation oncology, which SIO sees as a critical multidisciplinary partner to the success of the study. Upon completion, the study will enroll 120 subjects from across sites in the United States. Percutaneous ablation and RT have different mechanisms of alleviating pain and causing tumor death that may work synergistically. Radiation therapy is a widely accepted treatment for painful bone metastases and provides palliation of pain for patients. Percutaneous ablation, a minimally invasive therapy for painful metastatic bone disease, can be performed with thermal modalities (e.g., radiofrequency, microwave, cryoablation) and requires minimal recovery. About the Society of Interventional Oncology (SIO) SIO serves as the only membership-based organization dedicated to the emerging field of interventional oncology (IO), working to establish, nurture, and support IO as the fourth pillar of cancer therapy alongside medical, surgical, and radiation oncology worldwide. IO therapies, such as embolization and tumor ablation, combine the expertise of oncology and radiology and use imaging technology to diagnose and treat localized cancers in ways that are precisely targeted and minimally or non-invasive. For more information, please visit Contact InformationTaylor Marks Marketing Manager 6089313414 SOURCE: Society of Interventional Oncology press release
News24
4 hours ago
- News24
Is the ‘BBL smell' real? Leading plastic surgeon unpacks this phenomenon
'BBL smell' is an informal term used to describe unpleasant body odours that some patients report during the recovery phase of a Brazilian Butt Lift.
Yahoo
5 hours ago
- Yahoo
Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers
Strengthens Intellectual Property Estate for REQORSA Oncology Program with Immune Checkpoint Inhibitors AUSTIN, Texas, Aug. 18, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent to Genprex that covers the use of the Company's lead drug candidate, Reqorsa® Gene Therapy, in combination with PD-L1 antibodies, such as Tecentriq®. Similarly, the European Patent Office has issued a Notice of Allowance to Genprex for a patent covering the use of REQORSA in combination with PD-1 antibodies. Both patents will expire in 2037 at the earliest. "We are very proud to continue building a fortress of intellectual property protection around our oncology program for REQORSA, and these newly granted patents strengthen and expand our intellectual property estate for REQORSA in combination with immune checkpoint inhibitors applicable to our Acclaim-3 clinical trial," said Thomas Gallagher, Esq., Senior Vice President of Intellectual Property and Licensing at Genprex. Genprex has been granted patents for the use of REQORSA in combination with PD-L1 antibodies in Korea. Genprex is pursuing additional patent applications in Europe, Canada, Brazil, China and Israel. Should these applications grant, they would be applicable to Genprex's Acclaim-3 clinical trial. Genprex has been granted patents for the use of REQORSA in combination with PD-1 antibodies in the U.S., Japan, Mexico, Russia, Australia, Chile, China, Korea and Singapore. PD-L1 and PD-1 antibodies are a type of targeted immunotherapy and a part of a group of checkpoint inhibitor anti-cancer drugs that block the activity of PD-L1 and PD-1 immune checkpoint proteins present on the surface of cells. The Acclaim-3 study is a Phase 1/2 clinical trial that uses a combination of REQORSA and Genentech's Tecentriq® as maintenance therapy for patients with extensive stage small cell lung cancer (ES-SCLC) who are candidates for maintenance therapy after receiving Tecentriq and chemotherapy as initial standard treatment. The Acclaim-3 clinical trial has received U.S. Food and Drug Administration (FDA) Fast Track Designation for this patient population, and Acclaim-3 has received FDA Orphan Drug Designation. About Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach for Type 2 diabetes, where autoimmunity is not at play, GPX-002 is believed to rejuvenate and replenish exhausted beta cells. Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn. Cautionary Language Concerning Forward-Looking StatementsStatements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2024. Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials, its intended regulatory submissions and any resulting regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; Genprex's intellectual property and licenses, including the potential for future grants of patent applications globally; and Genprex's current expectations, estimates, forecasts and projections about the industry and markets in which it operates. These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law. Genprex, Inc.(877) 774-GNPX (4679) GNPX Investor Relationsinvestors@ GNPX Media ContactKalyn Dabbsmedia@ View original content to download multimedia: SOURCE Genprex, Inc. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
